Oral immunization with a recombinant Lactobacillus expressing CK6 fused with VP2 protein against IPNV in rainbow trout (Oncorhynchus mykiss)

Duan, Kexin; Hua, Xiaojing; Wang, Yuting; Wang, Yanxue; Chen, Yaping; Shi, Wen; Tang, Lijie; Li, Yijing

doi:10.1016/j.fsi.2018.09.034

Cited by 22 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were observed in mice and other animal models following oral administration of recombinant L. casei harboring major protective antigen VP4 of porcine rotavirus [ 23 ], recombinant protein of TGEV [ 41 ], or co-expressing epitopes of porcine parvovirus (PPV) and classical swine fever virus (CSFV) [ 42 ], indicating an efficient induction of protective immunity against various viral infections. In light of the valuable insights provided by these studies with genetically engineered L. casei carrying viral antigens, more in vivo studies focused on the expression of VP2 protein from infectious pancreatic necrosis virus (IPNV) in recombinant L. casei , which resulted in the stimulation of systemic and local mucosal immune responses, high-level production of IgM and IgT, and reduction of viral load in orally immunized rainbow trouts [ 26 , 43 ].…”

Section: Recombinant Probiotics As Inducers Of Humoral Immune Responsesmentioning

confidence: 99%

Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, the causative agent of COVID-19, now represents the sixth Public Health Emergency of International Concern (PHEIC)—as declared by the World Health Organization (WHO) since 2009. Considering that SARS-CoV-2 is mainly transmitted via the mucosal route, a therapy administered by this same route may represent a desirable approach to fight SARS-CoV-2 infection. It is now widely accepted that genetically modified microorganisms, including probiotics, represent attractive vehicles for oral or nasal mucosal delivery of therapeutic molecules. Previous studies have shown that the mucosal administration of therapeutic molecules is able to induce an immune response mediated by specific serum IgG and mucosal IgA antibodies along with mucosal cell-mediated immune responses, which effectively concur to neutralize and eradicate infections. Therefore, advances in the modulation of mucosal immune responses, and in particular the use of probiotics as live delivery vectors, may encourage prospective studies to assess the effectiveness of genetically modified probiotics for SARS-CoV-2 infection. Emerging trends in the ever-progressing field of vaccine development re-emphasize the contribution of adjuvants, along with optimization of codon usage (when designing a synthetic gene), expression level, and inoculation dose to elicit specific and potent protective immune responses. In this review, we will highlight the existing pre-clinical and clinical information on the use of genetically modified microorganisms in control strategies against respiratory and non-respiratory viruses. In addition, we will discuss some controversial aspects of the use of genetically modified probiotics in modulating the cross-talk between mucosal delivery of therapeutics and immune system modulation.

show abstract

Section: Recombinant Probiotics As Inducers Of Humoral Immune Responsesmentioning

confidence: 99%

Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Being the first barrier against the pathogens infections, mucosal immune system plays a critical role in pathogenic defense and induction of immunity. Many studies showed that oral live vector vaccine could simultaneously trigger the mucosal immune and systemic immune response of vaccinated animals [40–42]. A similar phenomenon was observed in this work: the specific IgM antibody against HIRRV were both detected in serum and gut mucus of flounders orally vaccinated with Ll:pSLC-G. Interestingly, the significant increase of antibody level was detected earlier in mucus, which indicated that mucosal immune response was quickly evoked and produced mucosal antibodies post oral vaccination.…”

Section: Discussionmentioning

confidence: 99%

“…In mouse model, several studies showed that LAB could exist in gut for a few days [44, 45], while some discovered that some of LAB species could not colonize the digestive tracts of man and animals, but can survive passage through the gut [28, 46]. In rainbow trout, approximately half proportions of lactobacillus were detected in the intestine at day 7 compared to the first day [40]. In the present work, we found that a portion of L. lactis NZ9000 has the ability to survive and adhere to the intestine in flounder and can last for at least 3 weeks.…”

Section: Discussionmentioning

confidence: 99%

Surface display of hirame novirhabdovirus (HIRRV) G protein in Lactococcus lactis and its immune protection in flounder (Paralichthys olivaceus)

et al. 2019

View full text Add to dashboard Cite

Background Hirame novirhabdovirus (HIRRV) can infect a wide range of marine and freshwater fish, causing huge economic losses to aquaculture industry. Vaccine development, especially oral vaccine, has become an effective and convenient way to control aquatic infectious diseases. HIRRV glycoprotein (G), an immunogenic viral protein is a potential vaccine candidate for prevention of the disease. Here, we aimed to construct a recombinant Lactococcus lactis strain expressing HIRRV-G on the cell surface as an oral vaccine to prevent HIRRV. Results Glycoprotein gene of HIRRV was successfully cloned and expressed in L. lactis NZ9000 in a surface-displayed form, yielding Ll:pSLC-G. An approximately 81 kDa recombinant G protein (containing LysM anchoring motif) was confirmed by SDS-PAGE, western blotting and mass spectrometry analysis. The surface-displayed G protein was also verified by immunofluorescence and flow cytometry assays. Furthermore, to evaluate the potential of Ll:pSLC-G as oral vaccine candidate, flounders were continuously fed with commercial diet pellets coated with 1.0 × 10 9 cfu/g of induced Ll:pSLC-G for 1 week. Four weeks later, booster vaccination was performed with the same procedure. Compared with the controls, Ll:pSLC-G elicited significantly higher levels of specific IgM against HIRRV in flounder gut mucus at the second week and in serum at the fourth week ( p < 0.05). Meanwhile, oral immunization with Ll:pSLC-G could provide 60.7% protection against HIRRV infection and a significantly lower virus load was detected than the controls on the third day post-challenge ( p < 0.01). Moreover, on the first day post 1-week feeding, approximately 10 4 –10 5 recombinant L. lactis cells were detected in every gram of foregut, midgut and hindgut of flounder, which were mainly localized at the bottom of gut mucus layer; and on day 21, 10 2 –10 3 L. lactis cells could still be recovered. Conclusions HIRRV-G protein was successfully expressed on the surface of L. lactis cells, which could trigger mucosal and humoral immune response of flounder and provide considerable immune protection against HIRRV. It suggests that genetically engineered L. lactis expressing G protein can be employed as a promising oral vaccine against HIRRV infection.

show abstract

“…Furthermore, oral vaccination employing bioencapsulation in live vehicles such as the brine shrimp Artemia [59], rotifers and water fleas [60] has been developed for larval fish that cannot feed on pelleted food. Oral antigen administration, including that of inactivated virus and recombinant viral antigens as well as DNA vaccines, provide effective protection for fishes and result in the upregulation of genes related to adaptive immunity [54], [55], [56], [61], [60], [62] and local and systemic antibody production [63], suggesting induced adaptive immunity in GALTs. However, recent studies reported that oral administration of alginate encapsulated DNA vaccines did not confer protection against spring viremia of carp virus (SVCV) [64] or koi herpes virus (KHV) in common carp [65].…”

Section: Oral Administration and Intubationmentioning

confidence: 99%

Mucosal delivery of fish vaccines: Local and systemic immunity following mucosal immunisations

Somamoto

Nakanishi²

2020

Fish & Shellfish Immunology

View full text Add to dashboard Cite

The mucosal organs of fishes are directly exposed to their aquatic environment, which is suited to the colonization and growth of microorganisms, and thus these barriers are considered to play an important role in maintaining homeostasis and preventing entry of invasive pathogens. Research on fish mucosal immunity have shown that mucosal organs such as gills, skin, intestines, and olfactory organs harbor lymphoid cells, including T and B cells as well as dendritic-like cells. Findings related to immune responses following direct administration of antigens into the mucosal organs could help to shed light upon the development of fish mucosal vaccines. The present review highlights vaccine delivery via mucosal organs, in particular focusing on methods other than those of typical mucosal vaccine platforms, such as oral and immersion vaccines. In addition, we propose the hypothesis that mucosal tissues are important sites for generating cell-mediated immunity following vaccination with extracellular antigens.

show abstract

Oral immunization with a recombinant Lactobacillus expressing CK6 fused with VP2 protein against IPNV in rainbow trout (Oncorhynchus mykiss)

Cited by 22 publications

References 47 publications

Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease

Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease

Surface display of hirame novirhabdovirus (HIRRV) G protein in Lactococcus lactis and its immune protection in flounder (Paralichthys olivaceus)

Mucosal delivery of fish vaccines: Local and systemic immunity following mucosal immunisations

Contact Info

Product

Resources

About